Rockefeller Capital Management’s 10x Genomics TXG Stock Holding History
Bought
Maintained
Sold
Other funds holding TXG
AIM
VPM
QCM
VCM
NAMA
Rockefeller Capital Management's TXG Position: Q1 2026 in Review
Rockefeller Capital Management increased its 10x Genomics (TXG) stake by 27% in Q1 2026, buying an estimated $92.9K and bringing the position to 21,831 shares worth $463K. The position accounts for ﹤0.01% of the portfolio, ranked #2015.
Rockefeller Capital Management first reported a position in TXG in Q1 2020 and has held it in 23 quarters since. The position peaked at $3.75M in Q2 2021. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.
- Rockefeller Capital Management held 21,831 shares of 10x Genomics worth $463K as of Q1 2026.
- Rockefeller Capital Management bought 4,645 10x Genomics shares in Q1 2026, an estimated $92.9K.
- 10x Genomics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #2015 holding.
- Rockefeller Capital Management first reported a position in 10x Genomics in Q1 2020 and has held it in 23 quarters since.
- Rockefeller Capital Management's 10x Genomics position peaked at $3.75M in Q2 2021.
- 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.
Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.